Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer
Affimed Therapeutics AG announced the appointment of Dr. Jens-Peter Marschner as Chief Medical Officer, effective October 1st, 2013.
Dr. Marschner recently joined Affimed from Merck KGaA. He has 18 years of professional experience in clinical development with a focus on biological compounds. Working in several pharmaceutical companies, he has been responsible for conducting clinical trials in all phases of development. Dr. Marschner led the clinical development team of cetuximab (Erbitux), a monoclonal antibody to treat colorectal cancer, which was successfully launched in 2004. During his career he has also been responsible for the early and late stage development of cancer immune therapies. As VP Global Medical Affairs at Merck KGaA Dr. Marschner gained comprehensive experience in market-related medical and scientific affairs, primarily in the field of oncology.
Dr. Adi Hoess, CEO of Affimed Therapeutics, commented: "I am delighted to welcome Jens-Peter as a key member of the Executive Management Board. His expert knowledge and experience in oncology drug development and management adds significantly to our company and our future. Jens-Peter's expertise will ensure that Affimed continues to build on its leadership in the development of bispecific immunotherapies."
Dr. Marschner initially trained and worked as a medical doctor. After finishing the clinical work at a general hospital (internal medicine) he worked at the University Hospital Frankfurt/Main where he became a board certified Clinical Pharmacologist. He started his pharmaceutical career in 1995 at Boehringer Mannheim, which is now part of Roche. After a shorter tenure at Bayer he joined Merck KGaA in 1999. Along with his responsibility for the development of several biological compounds he managed different global teams in Clinical Development and Medical Affairs.
Other news from the department people
